% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hofer:300097,
      author       = {T. P. Hofer and A. E. Nieto and L. Käsmann$^*$ and C. J.
                      Pelikan and J. Taugner and S. Mathur and C. Eze and C.
                      Belka$^*$ and F. Manapov$^*$ and E. Noessner},
      title        = {{E}arly recovery of leukocyte subsets is associated with
                      favorable progression-free survival in patients with
                      inoperable stage {II}/{III} {NSCLC} after multimodal
                      treatment: a prospective explorative study.},
      journal      = {Radiation oncology},
      volume       = {20},
      number       = {1},
      issn         = {1748-717X},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2025-00597},
      pages        = {43},
      year         = {2025},
      abstract     = {We explored the dynamic changes of major leukocyte subsets
                      during definitive treatment of patients with inoperable
                      stage II/III NSCLC lung cancer and correlated it to survival
                      to identify subpopulations associated with maximal patient
                      benefit.We analyzed peripheral blood of 20 patients, either
                      treated with thoracic radiotherapy (RT), concurrent
                      chemo-radiotherapy (cCRT), or cCRT with additional
                      immune-checkpoint inhibition therapy. Peripheral blood of 20
                      patients was collected at 9 timepoints before, during, and
                      up to 1 year post treatment and analyzed by multi-color flow
                      cytometry. Statistical analysis was conducted for leukocyte
                      subpopulations, IL-6, progression-free survival (PFS) and
                      overall survival (OS).Increase of absolute lymphocyte counts
                      (ALC) after the end of RT until 6 months thereafter was a
                      predictor of PFS. Baseline lymphocyte counts showed no
                      significant correlation to PFS or OS. Early recovery of
                      absolute counts (AC) at 3 weeks after RT, total CD3 +
                      T-cells, and CD8 + cytotoxic T-cells distinguished those
                      patients with favorable PFS (≥ 12 months) from all other
                      patients. Discriminant analysis identified B-cells,
                      neutrophil-lymphocyte-ratio (NLR), CD4 + T-helper-cells, and
                      NK-cells as predictors of favorable PFS. High variability in
                      IL-6 plasma concentration of consecutive measurements within
                      6 months after the end of RT correlated negatively with
                      PFS.Our results suggest that two parameters commonly
                      assessed in clinical routine can be used to predict patient
                      outcome. These are: early increase in CD8 + T-cell
                      lymphocyte count and variability in IL-6 plasma
                      concentration, that are correlated to patients with
                      favorable, respectively, poor outcome after definitive
                      therapy independent of treatment regimen.},
      keywords     = {Humans / Male / Carcinoma, Non-Small-Cell Lung: pathology /
                      Carcinoma, Non-Small-Cell Lung: mortality / Carcinoma,
                      Non-Small-Cell Lung: therapy / Carcinoma, Non-Small-Cell
                      Lung: blood / Carcinoma, Non-Small-Cell Lung: radiotherapy /
                      Female / Lung Neoplasms: pathology / Lung Neoplasms:
                      mortality / Lung Neoplasms: therapy / Lung Neoplasms: blood
                      / Lung Neoplasms: radiotherapy / Aged / Middle Aged /
                      Prospective Studies / Combined Modality Therapy /
                      Progression-Free Survival / Neoplasm Staging /
                      Chemoradiotherapy: mortality / Prognosis / Survival Rate /
                      Area under curve analysis (Other) / B-cells (Other) /
                      CD4 + T-cells (Other) / CD8 + T-cells (Other) /
                      Eosinophils (Other) / Immune checkpoint therapy (Other) /
                      Linear discriminant analysis (Other) / NK-cells (Other) /
                      Neutrophils (Other) / Non-small cell lung cancer (Other) /
                      Overall survival (Other) / Peripheral blood markers (Other)
                      / Progression-free survival (Other)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40114261},
      pmc          = {pmc:PMC11927295},
      doi          = {10.1186/s13014-025-02620-z},
      url          = {https://inrepo02.dkfz.de/record/300097},
}